2016年制药公司向日本痴呆症临床实践指南作者的付款情况。
Pharmaceutical company payments to the authors of the Japanese dementia clinical practice guidelines in 2016.
作者信息
Shimada Yuki, Ozaki Akihiko, Saito Hiroaki, Sawano Toyoaki, Tanimoto Tetsuya
机构信息
Department of Neurosurgery, Minamisoma Municipal General Hospital, Minamisoma, Fukushima, Japan.
Medical Governance Research Institute, Tokyo, Japan.
出版信息
Alzheimers Dement (N Y). 2019 Jun 24;5:228-230. doi: 10.1016/j.trci.2019.05.003. eCollection 2019.
INTRODUCTION
Financial relationships between pharmaceutical companies and dementia clinical practice guideline (CPG) authors are possibly biasing the recommendations in Japan. This study aimed to reveal characteristics and distribution of pharmaceutical payments made to Japanese dementia CPG authors and an extent of the transparency in the conflicts of interest disclosure among them.
METHODS
We retrospectively retrieved the publicly available data on payment to all the authors in the dementia CPGs by major pharmaceutical companies in Japan in 2016.
RESULTS
The total and mean payment values from pharmaceutical companies were $880,061 and $14,427, respectively. Of the 61 authors, 49 (80.3%) physicians received at least one payment. Financial relationships of the individual authors were not disclosed in the CPGs.
DISCUSSION
Pharmaceutical companies with antidementia drugs had strong financial relationships with the CPG authors. To guarantee fairness in their relationships, it is imperative to establish a framework to disclose the corporate financial conflicts of interest.
引言
制药公司与痴呆症临床实践指南（CPG）作者之间的财务关系可能会使日本的相关建议产生偏差。本研究旨在揭示日本制药公司向痴呆症CPG作者支付款项的特点和分布情况，以及他们在利益冲突披露方面的透明度。
方法
我们回顾性检索了2016年日本主要制药公司向痴呆症CPG所有作者支付款项的公开数据。
结果
制药公司支付的总金额和平均金额分别为880,061美元和14,427美元。在61位作者中，49位（80.3%）医生至少收到了一笔款项。CPG中未披露各作者的财务关系。
讨论
生产抗痴呆药物的制药公司与CPG作者有着密切的财务关系。为确保他们之间关系的公正性，必须建立一个框架来披露企业的财务利益冲突。
Zotero 插件